CRBU (Caribou Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CRBU officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | Timothy P Kelly | Chief Technology Officer | Sell | — | — |
| 2026-02-24 | Ruhi Ahmad Khan | Chief Business Officer | MIXED | — | — |
| 2026-02-24 | Tina M. Albertson | Chief Medical Officer | MIXED | — | — |
| 2026-02-24 | BARBARA G MCCLUNG | Chief Legal Officer | MIXED | — | — |
| 2026-02-24 | Timothy P Kelly | Chief Technology Officer | MIXED | — | — |
| 2026-02-20 | Dara Richardson-Heron | Director | A | — | — |
| 2026-02-20 | Natalie Sacks | Director | A | — | — |
| 2026-02-20 | DAVID LEE JOHNSON | Director | A | — | — |
| 2026-02-20 | Nancy Whiting | Director | A | — | — |
| 2026-02-20 | Ran Zheng | Director | A | — | — |
| 2026-02-20 | ANDREW GUGGENHIME | Director | A | — | — |
| 2026-02-20 | Scott Braunstein | Director | A | — | — |
| 2026-02-20 | Rachel E. Haurwitz | President and CEO | A | — | — |
| 2026-02-20 | Sriram Ryali | Chief Financial Officer | A | — | — |
| 2025-03-17 | Rachel E. Haurwitz | President and CEO | Buy | — | — |
| 2025-02-21 | Natalie Sacks | Director | A | — | — |
| 2025-02-21 | ANDREW GUGGENHIME | Director | A | — | — |
| 2025-02-21 | Ruhi Ahmad Khan | Chief Business Officer | MIXED | — | — |
| 2025-02-21 | Scott Braunstein | Director | A | — | — |
| 2025-02-21 | Tina M. Albertson | Chief Medical Officer | A | — | — |
| 2025-02-21 | BARBARA G MCCLUNG | Chief Legal Officer | MIXED | — | — |
| 2025-02-21 | Rachel E. Haurwitz | President and CEO | A | — | — |
| 2025-02-21 | Dara Richardson-Heron | Director | A | — | — |
| 2025-02-21 | Nancy Whiting | Director | A | — | — |
| 2025-02-21 | Steven Kanner | Chief Scientific Officer | MIXED | — | — |
| 2025-02-21 | Timothy P Kelly | Chief Technology Officer | A | — | — |
| 2025-02-21 | DAVID LEE JOHNSON | Director | A | — | — |
| 2025-02-21 | Ran Zheng | Director | A | — | — |
| 2025-01-30 | Sriram Ryali | Chief Financial Officer | Buy | — | — |
| 2025-01-10 | Sriram Ryali | Chief Financial Officer | A | — | — |
| 2024-11-22 | Ryan Fischesser | VP of Finance and Controller | A | — | — |
| 2024-08-20 | Tina M. Albertson | Chief Medical Officer | A | — | — |
| 2024-02-22 | Nancy Whiting | Director | A | — | — |
| 2024-02-22 | ANDREW GUGGENHIME | Director | A | — | — |
| 2024-02-22 | Ran Zheng | Director | A | — | — |
| 2024-02-22 | BARBARA G MCCLUNG | Chief Legal Officer | A | — | — |
| 2024-02-22 | Jason O'Byrne | Chief Financial Officer | A | — | — |
| 2024-02-22 | Steven Kanner | Chief Scientific Officer | A | — | — |
| 2024-02-22 | Natalie Sacks | Director | A | — | — |
| 2024-02-22 | Ruhi Ahmad Khan | Chief Business Officer | A | — | — |
| 2024-02-22 | Dara Richardson-Heron | Director | A | — | — |
| 2024-02-22 | Rachel E. Haurwitz | President and CEO | A | — | — |
| 2024-02-22 | Scott Braunstein | Director | A | — | — |
| 2024-02-22 | DAVID LEE JOHNSON | Director | A | — | — |
| 2024-02-08 | Steven Kanner | Chief Scientific Officer | M | — | — |
| 2024-01-09 | Timothy P Kelly | Chief Technology Officer | A | — | — |
| 2023-06-09 | Rachel E. Haurwitz | President and CEO | M | — | — |
| 2023-03-22 | Rachel E. Haurwitz | President and CEO | M | — | — |
| 2023-02-23 | Dara Richardson-Heron | Director | A | — | — |
| 2023-02-23 | Scott Braunstein | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 3,816,545 | — |
| — | Chief Legal Officer | 481,564 | — |
| — | Chief Scientific Officer | 431,556 | — |
| — | VP of Finance and Controller | 118,854 | — |
| — | Chief Business Officer | 111,936 | — |
| — | Chief Technology Officer | 73,125 | — |
| — | Chief Financial Officer | 72,360 | — |
| — | Chief Medical Officer | 69,589 | — |
| — | Chief Medical Officer | 59,373 | — |
| — | Chief Financial Officer | 59,224 | — |
| — | — | 17,572 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRBU quote page; the site-wide leaderboard is on the insider transactions hub.